Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Cardiovascular Risk in HIV
NCT02272946Phase 2Completed
- Start
- Sep 2015
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in cardiovascular disease (CVD). Started Sep 2015; status: completed.
02
Drugs
canakinumab
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02272946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02272946.